Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the European Commission has approved an update to the Alprolix® (eftrenonacog alfa) Summary of Product Characteristics (SmPC) to include additional information regarding use among previously untreated patients (PUPs) with haemophilia B. Alprolix is now the only extended half-life factor IX (FIX) product with safety and efficacy data in PUPs included in the SmPC. The data reinforces its favourable safety profile for use in all age groups.